CYAD-211

Overview

CYAD-211 is an allogeneic (donor) CAR T Cell therapy that targets the B-cell maturation antigen (BCMA) chimeric antigen receptor.

SparkCures ID 389
Developed By Celyad Therapeutics
Generic Name CYAD-211
Treatment Classifications
Treatment Targets

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Resources

There are no resources, links or videos to display for this treatment.